In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

The committee noted that semaglutide tablets 3 mg, 7 mg, and 14 mg are approved for marketing in India. The firm has claimed ...

MetaVia (MTVA) announced positive results from the 4-week multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, ...

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains ...

Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

Shares of Structure Therapeutics Inc ADR (NASDAQ: GPCR) climbed 6.8% following the news that Pfizer Inc. (NYSE: NYSE:PFE) has ...

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing a long-acting amylin analogue from Denmark's Gubra in a deal valued at more than $2.2 billion.

Cagrilintide is a long-acting agonist of amylin and calcitonin receptors in late phase trials for obesity. Here, authors present structures of cagilintide with each target receptor, revealing the ...

Diabetes Care. 2006;29(2):435-449.